Spyre Therapeutics(SYRE)
WALTHAM, MABiotechnology
Focus: Spyre Therapeutics is a public-stage biotechnology company focused on antibody-based therapeutics for immunology indications. The company is in early clinical development with a lean portfolio in Phase 1-2 trials.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
6+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at Spyre Therapeutics?
AI assessmentSpyre is a speculative early-stage bet suitable only for scientists seeking platform ownership and equity upside; not for those prioritizing stability or near-term revenue validation.
Why Work Here
- Antibody platform expertise in immunology offers deep technical specialization in a high-value modality.
- Recently went public with $189M cash position (FY 2025), providing medium-term runway for early-stage programs.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$886K
Pipeline & Clinical Trials
SPY002-091
HealthyClinical Trials (1)
NCT06672718A Study of SPY002-091 in Healthy Volunteers
Phase 1Help build intelligence for Spyre Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.